Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor used to treat type 2 diabetes, chronic kidney disease, and heart failure [75-77], also demonstrated similar effects (Fig. 2). This evidence concerns the gene SLC5A2 and heart failure.